Abstract: OBJECTIVE The application of PDCA cycle in rationalizing the clinical use of creatine phosphate sodium in pediatric department was explored to promote the rational use of adjuvant drug in the clinic. METHODS In retrospective analysis, 1 300 medical records of pediatric department involving creatine phosphate sodium were selected with HIS (Hospital information system), including 700 medical records from January, 2015 to July, 2016 before PDCA cycle management, 300 records from September, 2016 to February, 2017 after the first PDCA cycle management and 300 records from March to September, 2017 after the second PDCA cycle management. The use of creatine phosphate sodium was analyzed comparatively before and after PDCA cycle intervention. RESULTS After 2 cycles of PDCA cycle management intervention, the monthly DDDs value of creatine phosphate sodium in pediatric department was significantly decreased from 763 before PDCA cycle intervention to 193 after two PDCA cycles, and the rational rate of creatine phosphate sodium was significantly improved from 66.86% before intervention to 93.00% after two PDCA cycles. CONCLUSIONS PDCA cycle management could significantly promote continuous improvement for the clinical use of creatine phosphate sodium in pediatric department.